ArticleJournal of Alzheimer's disease : JAD2025
A comparison of drugs targeting the renin-angiotensin system and global cognition in aging.
Article in Journal of Alzheimer's disease : JAD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ang II-mediated effects on BBB integrity in psychiatric and neurological disorders.Progress in neuro-psychopharmacology & biological psychiatry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BackgroundHypertension (HTN) is a major risk factor for Alzheimer's disease (AD) and related dementias. Renin-angiotensin system (RAS) medications, including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), have been proposed to mitigate cognitive decline, but evidence remains inconsistent.ObjectiveCompare global cognition over time among ARB, ACEI, and non-RAS drug users.MethodsData from the Rush Memory and Aging Project (1997-2006) included 2019 participants. Global cognition was assessed using a composite z-score of 19 cognitive tests. Participants were categorized by medication use: ARB, ACEI, or non-RAS. Analysis of covariance (ANCOVA) was performed to compare cognitive outcomes over 9 years, adjusting for baseline cognition, social determinants, and medical factors. Subgroup analyses evaluated cognitive domains and the impact of HTN.ResultsAt baseline, ARB and ACEI users had more vascular risk factors and medical conditions than non-RAS users. At 9 years, ARB users had slightly better global cognitive outcomes compared to ACEI (LS-mean difference: 0.015, 95% CI [-0.175, 0.205]) and non-RAS users (LS-mean difference: 0.06, 95% CI [-0.11, 0.23]), though differences were not statistically significant. ACEI users showed significant improvement in working memory compared to non-RAS users (LS-mean: 0.157, 95% CI [0.002, 0.313]). Among participants without HTN, ACEI use was associated with significantly reduced cognitive decline compared to non-RAS use.ConclusionsARBs may benefit global cognitive function, while ACEIs may yield improvements in specific domains like working memory. Further studies are needed to confirm these findings and explore the impact of drug characteristics such as blood-brain-barrier penetration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.